Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387135714> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W4387135714 abstract "<h3>Introduction/Background</h3> Few data are available on Bevacizumab in neoadjuvant chemotherapy (NACT) setting for High Grade Serous ovarian Cancer (HGSC) patients. We investigate the effect of Bevacizumab addition to standard NACT regimen (Carboplatin and Paclitaxel) after Interval Debulking Surgery (IDS) failure following the first 3 NACT cycles. <h3>Methodology</h3> This is a retrospective, single-centre study enrolling FIGO stage IIIC-IV HGSC patients (regardless of BRCA status) still considered unresectable after 3 cycles of NACT. Main inclusion criteria were: ECOG 0, age ranging from 40 to 75 years old, no contraindications to Bevacizumab administration. Patients were stratified whether they added Bevacizumab from cycle 4 to 6 (CPB group) or not (CP group). Primary endpoint was the cytoreduction rate after 6 cycles (delayed IDS). <h3>Results</h3> From 2017 to 2021, 58 (23%) patients received neoadjuvant Bevacizumab (CPB), and 190 (77%) did not (CP). Only 118 (48%) women received delayed IDS: 31 in the CBP group (46%) and 87 (53%) in the CP one (p=0.38); complete gross resection was achieved in 26 (84%) and 77 (88%) patients, respectively (p=0.72). We did not find any difference in terms of severe early postoperative complications (8% for the CP group and 10% for the CPB one, p=0.069). Median Overall Survival (OS) was not significantly different between the two groups for those patients undergoing delayed IDS (not reached in the CPB and 38 months in the CP group, p=0.55). Conversely, among 130 (52%) patients still unresectable after 6 cycles, Bevacizumab had a significant effect on the CPB group’s median OS compared to the CP one (not reached vs 18 months, p=0.015). <h3>Conclusion</h3> The use of Bevacizumab in neoadjuvant setting does not seem to increase the delayed IDS rate, nonetheless it prolongs OS for those patients persisting unsuitable for surgery. Thus, its administration may be an option in selected patients after failure of early IDS. <h3>Disclosures</h3> None" @default.
- W4387135714 created "2023-09-29" @default.
- W4387135714 creator A5009089046 @default.
- W4387135714 creator A5029193050 @default.
- W4387135714 creator A5034390518 @default.
- W4387135714 creator A5051165462 @default.
- W4387135714 creator A5070317974 @default.
- W4387135714 creator A5071726917 @default.
- W4387135714 creator A5073768160 @default.
- W4387135714 creator A5076497986 @default.
- W4387135714 creator A5086124010 @default.
- W4387135714 date "2023-09-01" @default.
- W4387135714 modified "2023-09-29" @default.
- W4387135714 title "#599 Failure of early interval debulking surgery after standard neoadjuvant chemotherapy: may bevacizumab add something? a large retrospective study" @default.
- W4387135714 doi "https://doi.org/10.1136/ijgc-2023-esgo.611" @default.
- W4387135714 hasPublicationYear "2023" @default.
- W4387135714 type Work @default.
- W4387135714 citedByCount "0" @default.
- W4387135714 crossrefType "proceedings-article" @default.
- W4387135714 hasAuthorship W4387135714A5009089046 @default.
- W4387135714 hasAuthorship W4387135714A5029193050 @default.
- W4387135714 hasAuthorship W4387135714A5034390518 @default.
- W4387135714 hasAuthorship W4387135714A5051165462 @default.
- W4387135714 hasAuthorship W4387135714A5070317974 @default.
- W4387135714 hasAuthorship W4387135714A5071726917 @default.
- W4387135714 hasAuthorship W4387135714A5073768160 @default.
- W4387135714 hasAuthorship W4387135714A5076497986 @default.
- W4387135714 hasAuthorship W4387135714A5086124010 @default.
- W4387135714 hasBestOaLocation W43871357141 @default.
- W4387135714 hasConcept C121608353 @default.
- W4387135714 hasConcept C126322002 @default.
- W4387135714 hasConcept C141071460 @default.
- W4387135714 hasConcept C143998085 @default.
- W4387135714 hasConcept C167135981 @default.
- W4387135714 hasConcept C2776694085 @default.
- W4387135714 hasConcept C2777802072 @default.
- W4387135714 hasConcept C2778239845 @default.
- W4387135714 hasConcept C2778292576 @default.
- W4387135714 hasConcept C2780427987 @default.
- W4387135714 hasConcept C2781100745 @default.
- W4387135714 hasConcept C2781413609 @default.
- W4387135714 hasConcept C2781451048 @default.
- W4387135714 hasConcept C530470458 @default.
- W4387135714 hasConcept C71924100 @default.
- W4387135714 hasConceptScore W4387135714C121608353 @default.
- W4387135714 hasConceptScore W4387135714C126322002 @default.
- W4387135714 hasConceptScore W4387135714C141071460 @default.
- W4387135714 hasConceptScore W4387135714C143998085 @default.
- W4387135714 hasConceptScore W4387135714C167135981 @default.
- W4387135714 hasConceptScore W4387135714C2776694085 @default.
- W4387135714 hasConceptScore W4387135714C2777802072 @default.
- W4387135714 hasConceptScore W4387135714C2778239845 @default.
- W4387135714 hasConceptScore W4387135714C2778292576 @default.
- W4387135714 hasConceptScore W4387135714C2780427987 @default.
- W4387135714 hasConceptScore W4387135714C2781100745 @default.
- W4387135714 hasConceptScore W4387135714C2781413609 @default.
- W4387135714 hasConceptScore W4387135714C2781451048 @default.
- W4387135714 hasConceptScore W4387135714C530470458 @default.
- W4387135714 hasConceptScore W4387135714C71924100 @default.
- W4387135714 hasLocation W43871357141 @default.
- W4387135714 hasOpenAccess W4387135714 @default.
- W4387135714 hasPrimaryLocation W43871357141 @default.
- W4387135714 hasRelatedWork W1967715255 @default.
- W4387135714 hasRelatedWork W1970429237 @default.
- W4387135714 hasRelatedWork W2088563918 @default.
- W4387135714 hasRelatedWork W2418376607 @default.
- W4387135714 hasRelatedWork W3016694168 @default.
- W4387135714 hasRelatedWork W3047309708 @default.
- W4387135714 hasRelatedWork W3101616931 @default.
- W4387135714 hasRelatedWork W59268075 @default.
- W4387135714 hasRelatedWork W757206253 @default.
- W4387135714 hasRelatedWork W99287364 @default.
- W4387135714 isParatext "false" @default.
- W4387135714 isRetracted "false" @default.
- W4387135714 workType "article" @default.